Traditional drug discovery and development are often time-consuming and high risk. Repurposing/repositioning of approved drugs offers a relatively low-cost and high-efficiency approach toward rapid development of efficacious treatments. The emergence of large-scale, heterogeneous biological networks has offered unprecedented opportunities for developing in silico drug repositioning approaches. However, capturing highly non-linear, heterogeneous network structures by most existing approaches for drug repositioning has been challenging. In this study, we developed a network-based deep-learning approach, termed deepDR, for in silico drug repurposing by integrating 10 networks: one drug–disease, one drug-side-effect, one drug–target and seven drug–drug networks. Specifically, deepDR learns high-level features of drugs from the heterogeneous networks by a multi-modal deep autoencoder. Then the learned low-dimensional representation of drugs together with clinically reported drug–disease pairs are encoded and decoded collectively via a variational autoencoder to infer candidates for approved drugs for which they were not originally approved. We found that deepDR revealed high performance [the area under receiver operating characteristic curve (AUROC) = 0.908], outperforming conventional network-based or machine learning-based approaches. Importantly, deepDR-predicted drug–disease associations were validated by the ClinicalTrials.gov database (AUROC = 0.826) and we showcased several novel deepDR-predicted approved drugs for Alzheimer’s disease (e.g. risperidone and aripiprazole) and Parkinson’s disease (e.g. methylphenidate and pergolide). Source code and data can be downloaded from https://github.com/ChengF-Lab/deepDR Supplementary data are available online at Bioinformatics.

Identifying drug-target interactions will greatly narrow down the scope of search of candidate medications, and thus can serve as the vital first step in drug discovery. Considering that in vitro experiments are extremely costly and time-consuming, high efficiency computational prediction methods could serve as promising strategies for drug-target interaction (DTI) prediction. In this review, our goal is to focus on machine learning approaches and provide a comprehensive overview. First, we summarize a brief list of databases frequently used in drug discovery. Next, we adopt a hierarchical classification scheme and introduce several representative methods of each category, especially the recent state-of-the-art methods. In addition, we compare the advantages and limitations of methods in each category. Lastly, we discuss the remaining challenges and future outlook of machine learning in DTI prediction. This article may provide a reference and tutorial insights on machine learning-based DTI prediction for future researchers.

The increase in biological data and the formation of various biomolecule interaction databases enable us to obtain diverse biological networks. These biological networks provide a wealth of raw materials for further understanding of biological systems, the discovery of complex diseases and the search for therapeutic drugs. However, the increase in data also increases the difficulty of biological networks analysis. Therefore, algorithms that can handle large, heterogeneous and complex data are needed to better analyze the data of these network structures and mine their useful information. Deep learning is a branch of machine learning that extracts more abstract features from a larger set of training data. Through the establishment of an artificial neural network with a network hierarchy structure, deep learning can extract and screen the input information layer by layer and has representation learning ability. The improved deep learning algorithm can be used to process complex and heterogeneous graph data structures and is increasingly being applied to the mining of network data information. In this paper, we first introduce the used network data deep learning models. After words, we summarize the application of deep learning on biological networks. Finally, we discuss the future development prospects of this field.

Motivation: Identification of enhancer–promoter interactions (EPIs) is of great significance to human development. However, experimental methods to identify EPIs cost too much in terms of time, manpower and money. Therefore, more and more research efforts are focused on developing computational methods to solve this problem. Unfortunately, most existing computational methods require a variety of genomic data, which are not always available, especially for a new cell line. Therefore, it limits the large-scale practical application of methods. As an alternative, computational methods using sequences only have great genome-scale application prospects. Results: In this article, we propose a new deep learning method, namely EPIVAN, that enables predicting long-range EPIs using only genomic sequences. To explore the key sequential characteristics, we first use pre-trained DNA vectors to encode enhancers and promoters; afterwards, we use one-dimensional convolution and gated recurrent unit to extract local and global features; lastly, attention mechanism is used to boost the contribution of key features, further improving the performance of EPIVAN. Benchmarking comparisons on six cell lines show that EPIVAN performs better than state-of-the-art predictors. Moreover, we build a general model, which has transfer ability and can be used to predict EPIs in various cell lines. Availability and implementation: The source code and data are available at: https://github.com/hzy95/EPIVAN.

Identifying new lead molecules to treat cancer requires more than a decade of dedicated effort. Before selected drug candidates are used in the clinic, their anti-cancer activity is generally validated by in vitro cellular experiments. Therefore, accurate prediction of cancer drug response is a critical and challenging task for anti-cancer drugs design and precision medicine. With the development of pharmacogenomics, the combination of efficient drug feature extraction methods and omics data has made it possible to use computational models to assist in drug response prediction. In this study, we propose DeepTTA, a novel end-to-end deep learning model that utilizes transformer for drug representation learning and a multilayer neural network for transcriptomic data prediction of the anti-cancer drug responses. Specifically, DeepTTA uses transcriptomic gene expression data and chemical substructures of drugs for drug response prediction. Compared to existing methods, DeepTTA achieved higher performance in terms of root mean square error, Pearson correlation coefficient and Spearman’s rank correlation coefficient on multiple test sets. Moreover, we discovered that anti-cancer drugs bortezomib and dactinomycin provide a potential therapeutic option with multiple clinical indications. With its excellent performance, DeepTTA is expected to be an effective method in cancer drug design.

As the best substitute for antibiotics, antimicrobial peptides (AMPs) have important research significance. Due to the high cost and difficulty of experimental methods for identifying AMPs, more and more researches are focused on using computational methods to solve this problem. Most of the existing calculation methods can identify AMPs through the sequence itself, but there is still room for improvement in recognition accuracy, and there is a problem that the constructed model cannot be universal in each dataset. The pre-training strategy has been applied to many tasks in natural language processing (NLP) and has achieved gratifying results. It also has great application prospects in the field of AMP recognition and prediction. In this paper, we apply the pre-training strategy to the model training of AMP classifiers and propose a novel recognition algorithm. Our model is constructed based on the BERT model, pre-trained with the protein data from UniProt, and then fine-tuned and evaluated on six AMP datasets with large differences. Our model is superior to the existing methods and achieves the goal of accurate identification of datasets with small sample size. We try different word segmentation methods for peptide chains and prove the influence of pre-training steps and balancing datasets on the recognition effect. We find that pre-training on a large number of diverse AMP data, followed by fine-tuning on new data, is beneficial for capturing both new data’s specific features and common features between AMP sequences. Finally, we construct a new AMP dataset, on which we train a general AMP recognition model.